PMID: 22335138Feb 18, 2012Paper

Risk factors of graft-versus-host disease in patients after allogeneic stem cell transplantation

Wiadomości lekarskie : organ Polskiego Towarzystwa Lekarskiego
Irena KozakRenata Górska

Abstract

Graft-versus-host disease (GVHD) is the most common and most serious complication of allogeneic hematopoetic stem cell transplantation (HSCT). The aim of this study was to assess the incidence of GVHD after allogeneic HSCT depending on the diagnosis and risk factors. The study group comprised 78 patients aged 18 to 61 in whom allogeneic transplantation of hematopoietic stem cell in the Department and Clinic of Hematology, Oncology and Internal Diseases of Medical University in Warsaw (Poland) was performed. Acute form of GVHD was significantly more often occurred after total body irradiation (TBI) for patients with TBI who did not (p < 0.05). Risk factors for aGVHD were: age of the recipient, acute myeloid leukemia, myeloablative conditioning, TBI and unrelated donor.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.